NCT07014904

Brief Summary

the investigators aim in this study to investigate the potential association of single gene polymorphisms of CTLA-4 (SNPs; rs: 3087243) using real-time PCR in children with primary ITP.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
14mo left

Started Aug 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
Aug 2025Jul 2027

First Submitted

Initial submission to the registry

June 3, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 11, 2025

Completed
2 months until next milestone

Study Start

First participant enrolled

August 20, 2025

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 4, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2027

Last Updated

June 17, 2025

Status Verified

May 1, 2025

Enrollment Period

1.8 years

First QC Date

June 3, 2025

Last Update Submit

June 12, 2025

Conditions

ITP - Immune Thrombocytopenia

Outcome Measures

Primary Outcomes (1)

  • investigate the potential association of single gene polymorphisms of CTLA-4 (SNPs; rs: 3087243) using real-time PCR in children with primary ITP.

    Baseline

Study Arms (1)

investigate the potential association of single gene polymorphisms of CTLA-4 (SNPs; rs: 3087243) usi

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

1. Full history taking. 2. Through clinical examination. 3. Laboratory investigations: a .Complete blood count with platelet indices: Mean Platelet Volume, Plateletcrit, platelet distribution width (MPV, PCT \& PDW). b. Genotyping of rs3087243-related single-nucleotide polymorphism.

You may not qualify if:

  • Refusal to sign an informed written consent, patient with persistent ITP, patient with chronic ITP, patient with secondary immune thrombocytopenia and patient age \< 1 year or \> 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic

Condition Hierarchy (Ancestors)

Purpura, ThrombocytopenicPurpuraBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesThrombotic MicroangiopathiesThrombocytopeniaBlood Platelet DisordersCytopeniaHemorrhagic DisordersAutoimmune DiseasesImmune System DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsSkin ManifestationsSigns and Symptoms

Central Study Contacts

Reham Elsayed Mohamed Ail Reham Elsayed Mohamed Ail, MD

CONTACT

01013757753Remohelmy1992@gmail.com

Douaa Mohammed Sayed Douaa Mohammed Sayed, Prof.Dr

CONTACT

01006261987

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 3, 2025

First Posted

June 11, 2025

Study Start

August 20, 2025

Primary Completion (Estimated)

June 4, 2027

Study Completion (Estimated)

July 20, 2027

Last Updated

June 17, 2025

Record last verified: 2025-05